Role of cyclodextrins in improving oral drug delivery

American Journal of Drug Delivery

Volumn 2, Issue 4, 2004, Pages 261-275

  Loftsson, Thorsteinn ^a   Brewster, Marcus E ^b   Másson, Már ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALBENDAZOLE; BENDROFLUMETHIAZIDE; BENEXATE; CEFOTIAM; CEFOTIAM HEXETIL; CHLORAMPHENICOL; CHLOROTHIAZIDE; CISAPRIDE; CLOROCIL; CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; DEXAMETHASONE; DEXOCORT; DICLOFENAC; ESTRADIOL; GLYCERYL TRINITRATE; GLYMESASON; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; INDOMETACIN; IODINE; ITRACONAZOLE; MENA GARGLE; MITOMYCIN C; NICOTINE GUM; NIMEDEX; NIMESULIDE; NITROPEN; OMEETA; OMEPRAZOLE; PIROXICAM; PIROXICAM BETA CYCLODEXTRIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAVASTIN; TIAPROFENIC ACID; UNINDEXED DRUG; VORICONAZOLE; ZIPRASIDONE;

AQUEOUS SOLUTION; CALCULATION; CHEMICAL MODIFICATION; COMPLEX FORMATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; EXCIPIENT COMPATIBILITY; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; THEORETICAL MODEL; UNITED STATES;

EID: 11044221846     PISSN: 11759038     EISSN: None     Source Type: Journal    
DOI: 10.2165/00137696-200402040-00006     Document Type: Review

References (157)

1. Dressman J, Butler J, Hempenstall J, et al. The BCS: where do we go from here? Pharm Tech North Am 2001; 25 (7): 68-76
2. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computatorial approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26
3. Duchêne D, editor. New trends in cyclodextrins and derivatives. Paris: Editions de Santé, 1991
4. Duchêne D. Cyclodextrins and their industrial uses. Paris: Editions de Santé, 1987
5. Szejtli J. Cyclodextrin technology. Dordrecht: Kluwer Academic Publisher, 1988
6. Frömming KH, Szejtli J. Cyclodextrins in pharmacy. Dordrecht: Kluwer Academic Publishers, 1994
7. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: 1. Drug solubilization and stabilization. J Pharm Sci 1996; 85 (10): 1017-25
8. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins: 2. In vivo drug delivery. J Pharm Sci 1996; 85 (11 : 1142-68
9. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins: III. Toxicological issues and safety evaluation. J Pharm Sci 1997; 86 (2): 147-62
10. Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res 1997; 14 (5): 556-67
11. Uekama K, editor. Cyclodextrins in drug delivery in Adv. Drug Deliv Rev 1999; 36 (1): 1-141
12. D'Souza VT, Lipkowitz KB, editors. Cyclodextrins: introduction. Chem Rev 1998; 98 (5): 1741-2
13. Lennernäs H. Human intestinal permeability. J Pharm Sci 1998; 87: 403-10
14. van de Waterbeemd H. The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. Eur J Pharm Sci 1998; 7: 1-3
15. Yoshida F, Topliss JG. QSAR model for drug human oral bioavailability. J Med Chem 2000; 43: 2575-85
16. Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-20
17. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system: new scientific approaches to international regulatory standards. Eur J Pharm Biopharm 2000; 50: 3-12
18. Hörter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 2001; 46: 75-87
19. US FDA, Center for Drug Evaluation and Research: The biopharmaceutics classification system (BCS) guidance [online]. Available from URL: www.fda.gov/ cder/OPS/BSC_guidance.htm [Accessed 2004 Oct 18]
20. Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 2002; 19: 921-5
21. Yazdanian M, Briggs K, Jankovsky C, et al. The 'high solubility' definition of current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm Res 2004; 21: 293-9
22. Szejtli J. Cyclodextrins and their inclusion complexes: Akademiai Kiadó, Budapest; 1982
23. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev 1998; 98: 2045-76
24. Thompson DO. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst 1997; 14: 1-104
25. Evaluation of certain food additives and contaminants, WHO Technical Report Series No. 909. Geneva: World Health Organization, 2002
26. Uekama K. Recent aspects of pharmaceutical application of cyclodextrins. J Incl Phenom Macroc Chem 2002; 44: 3-7
27. Bergeron RJ. Cycloamylose-substrate binding. In: Attwood JL, Bavies JED, MacNicol DD, editors. Inclusion compounds. London: Academic Press, 1984: 391-443
28. Liu L, Guo Q-X. The driving forces in the inclusion complexation of cyclodextrins. J Incl Phenom Macroc Chem 2002; 42: 1-14
29. Connors KA. Population characteristics of cyclodextrin complex stabilities in aqueous solution. J Pharm Sci 1995; 84: 843-8
30. Connors KA. The stability of cyclodextrin complexes in solution. Chem Rev 1997; 97: 1325-57
31. Rao VM, Stella VJ. When can cyclodextrins be considered for solubilizing purposes? J Pharm Sci 2003; 92: 927-32
32. Loftsson T, Magnúsdóttir A, Másson M, et al. Self-association and cyclodextrin solubilization of drugs. J Pharm Sci 2002; 91: 2307-16
33. Loftsson T, Másson M, Brewster ME. Self-association of cyclodextrins and cyclodextrin complexes. J Pharm Sci 2004; 93: 1091-9
34. Loftsson T. Effects of cyclodextrins on chemical stability of drugs in aqueous solutions. Drug Stability 1995; 1: 22-33
35. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersion. Eur J Pharm Biopharm 2000; 50: 47-60
36. Serajuddin AT. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems and recent break-through. J Pharm Sci 1999; 88: 1058-66
37. Corrigan OI, Stanley CT. Dissolution properties of phenobarbitone-β-cyclodextrin systems. Pharm Acta Helv 1981; 56: 204-8
38. Corrigan OI, Stanley CT. Mechanism of drug dissolution rate enhancement from β-cyclodextrin-drug systems. J Pharm Pharmacol 1982; 34: 621-6
39. Loftsson T, Másson M, Sigurjónsdóttir JF. Methods to enhance the complexation efficiency of cyclodextrins. STP Pharma Sci 1999; 9: 237-42
40. Loftsson T, Másson M. The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J Drug Del Sci Tech 2004; 14: 35-43
41. Krishnamoorthy R, Mitra AK. Complexation of weak acids and basis with cyclodextrins: effects of substrate ionization on the estimation and interpretation of association constants. Int J Pharm Advances 1996; 1: 330-43
42. Redenti E, Szente L, Szejtli J. Cyclodextrin complexes of salts of acidic drugs: thermodynamic properties, structural features, and pharmaceutical applications. J Pharm Sci 2001; 90: 979-86
43. Redenti E, Szente L, Szejtli J. Drug/cyclodextrin/hydroxy acid multicomponent systems: properties and pharmaceutical applications. J Pharm Sci 2000; 89: 1-8
44. Loftsson T, Sigurdsson HH, Másson M, et al. Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs. Pharmazie 2004; 59: 25-9
45. Loftsson T, Matthiasson K, Másson M. The effects of organic salts on the cyclodextrin solubilization of drugs. Int J Pharm 2003; 262: 101-7
46. Li P, Tabibi E, Yalkowsky SH. Combined effect of complexation and pH on solubilization. J Pharm Sci 1998; 87: 1535-7
47. Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001; 225: 15-30
48. Loftsson T, Sigfúisson SD, Sigurdsson HH, et al. The effects of cyclodextrins on topical delivery of hydrocortisone: the aqueous diffusion layer. STP Pharma Sci 2003; 13: 125-31
49. Matsuda H, Arima H. Cyclodextrins in transdermal and rectal delivery. Adv Drug Deliv Rev 1999; 36: 81-99
50. Legendre JY, Rault I, Petit A, et al. Effects of β-cyclodextrins on skin: implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977. Eur J Pharm Sci 1995; 3: 311-22
51. Vitória M, Bentley B, Renata F, et al. Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J Pharm Pharmacol 1997; 49: 397-402
52. Arima H, Miyaji T, Irie T, et al. Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by β-cyclodextrin derivatives in hydrophilic ointment. Chem Pharm Bull 1996; 44: 582-6
53. Arima, H, Miyaji T, Irie T, et al. Enhancing effect of hydroxypropyl-β-cyclodextrin on cutaneous penetration activation of ethyl 4-biphenylyl acetate in hairless mouse skin. Eur J Pharm Sci 1998; 6: 53-9
54. Irie T, Wakamatsu K, Arima H, et al. Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int J Pharm 1992; 84: 129-39
55. Moffat AC, Osselton MD, Widdop B, editors. Clarke's analysis of drugs and poisons. 3rd ed. London: Pharmaceutical Press, 2004
56. Luengo J, Aránguiz T, Sepúlveda J, et al. Preliminary pharmacokinetic study of different preparations of acyclovir with β-cyclodextrin. J Pharm Sci 2002; 91: 2593-8
57. Evrard B, Chiap P, DeTullio P, et al. Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-β-cyclodextrin. J Control Release 2002; 85: 45-50
58. García JJ, Bolás F, Torrado JJ. Bioavailability and efficiency characteristics of two different oral liquid formulations of albendazole. Int J Pharm 2003; 250: 351-8
59. Castillo JA, Palomo-Canales J, Garcia JJ, et al. Preparation and characterization of albendazole β-cyclodextrin complexes. Drug Dev Ind Pharm 1999; 25: 1241-8
60. Fathy M, Sheha M. In vitro and in vivo evaluation of an amylobarbitone/hydroxypropyl-β-cyclodextrin complex prepared by a freeze-drying method. Pharmazie 2000; 55: 513-7
61. Wong JW, Yuen KH. Improved oral bioavailability of artemisinin through inclusion complexation with β- and γ -cyclodextrins. Int J Pharm 2001; 227: 177-85
62. Teixeira LR, Sinisterra RD, Vieira RP, et al. Inclusion of benzaldehyde semi-carbazone into β-cyclodextrin produces a very effective anticonvulsant formulation. J Incl Phenom Macroc Chem 2003; 47: 77-82
63. Puglisi G, Santagati NA, Ventura CA, et al. Enhancement of 4-biphenylacetic acid bioavailability in rats by its β-cyclodextrin complex after oral administration. J Pharm Pharmacol 1991; 43: 430-2
64. Puglisi G, Ventura CA, Spadaro A, et al. Differential-effects of modified β-cyclodextrins on pharmacological activity and bioavailability of 4-biphenylacetic acid in rats after oral administration. J Pharm Pharmacol 1995; 47: 120-3
65. Hatanaka H, Komada F, Mishima Y, et al. Improved bioavailability of paraboronophenylalanine by cyclodextrin complexation. J Pharm Sci 1993; 82: 1054-7
66. El-Gindy GA, Mohammed FA, Salem SY. Preparation, pharmacokinetic and pharmacodynamic evaluation of carbamazepine inclusion complexes with cyclodextrins. STP Pharma Sci 2002; 12: 369-78
67. Brewster ME, Anderson WR, Meinsma D, et al. Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-β-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. J Pharm Sci 1997; 86: 335-9
68. Betlach CJ, Gonzalez MA, McKiernan BC, et al. Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex. J Pharm Sci 1993; 82: 1058-60
69. Choudhury S, Nelson KF. Improvement of oral bioavailability of carbamazepine by inclusion in 2-hydroxypropyl-β-cyclodextrin. Int J Pharm 1992; 85: 175-80
70. Koester LS, Bertuol JB, Groch KR, et al. Bioavailability of carbamazepine: β-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets. Eur J Pharm Sci 2004; 22: 201-7
71. Fekkes D, Tuiten A, Bom I, et al. Pharmacokinetics of the b-carboline norharman in man. Life Sci 2001; 69: 2113-21
72. Hirayama F, Usami M, Kimura K, et al. Crystallization and polymorphic transition behavior of chloramphemicol palmitate in 2-hydroxypropyl-β-cyclodextrin matrix. Eur J Pharm Biopharm 1997; 5: 23-30
73. Tokumura T, Tsushima Y, Kayano M, et al. Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent. J Pharm Sci 1985; 74: 496-7
74. Järvinen T, Järvinen K, Schwarting N, et al. β-Cyclodextrin derivatives, SBE4-b-CD and HP-b-CD, increase the oral bioavailability of cinnarizine in beagle dogs. J Pharm Sci 1995; 84: 295-9
75. Tokumura T, Nanba M, Tsushima Y, et al. Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent. J Pharm Sci 1986; 75: 391-4
76. Yoo SD, Yoon BM, Lee HS, et al. Increased bioavailability of clomipramine after sublingual administration in rats. J Pharm Sci 1999; 88: 1119-21
77. Miyake K, Irie T, Hirayama F, et al. Improve solubility and oral bioavailability of cyclosporin A by hydrophilic cyclodextrin complexation. In: Torres Labandeira JJ, Vila-Jato JL, editors. Proceedings of the Ninth International Symposium on Cyclodextrins; 1998 Jun 3; Santiago de Compostela. Dordrecht: Kluwer Academic Publishers, 1999: 293-6
78. Miyake K, Arima H, Irie T, et al. Enhanced absorption of cyclosporin A by complexation with dimethyl-β-cyclodextrin in bile duct-cannulated and -non-cannulated rats. Biol Pharm Bull 1999; 22: 66-72
79. Jain AC, Aungst BJ, Adeyeye MC. Development and in vivo evaluation of buccal tablets prepared using danazole-sulfobutylether 7β-cyclodextrin (SBE 7) complexes. J Pharm Sci 2002; 91: 1659-68
80. Badawy SIF, Ghorab MM, Adeyeye CM. Characterization and bioavailability of danazol-hydroxypropyl-β-cyclodextrin coprecipitates. Int J Pharm 1996; 128: 45-54
81. Liversidge GG, Cundy KC. Particle-size reduction for improvement of oral bioavailability of hydrophobic drugs: 1. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995; 125: 91-7
82. Badawy SIF, Ghorab MM, Adeyeye CM. Bioavailability of danazol-hydroxypropyl-β-cyclodextrin complex by different routes of administration. Int J Pharm 1996; 145: 137-43
83. Corvi Mora P, Cirri M, Allolio B, et al. Enhancement of dehydroepianhydrosterone solubility and bioavailability by ternary complexation with α-cyclodextrin and glycine. J Pharm Sci 2003; 92: 2177-84
84. Uekama K, Fujinaga T, Hirayama F, et al. Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation. J Pharm Sci 1983; 72: 1338-41
85. Le Corre P, Dollo G, Chevanne F, et al. Influence of hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin on diphenhydramine intestinal absorption in a rat in situ model. Int J Pharm 1998; 169: 221-8
86. Ricevuti G, Mazzone A, Pasotti D, et al. Pharmacokinetics of dipyridamole-β-cyclodextrin complex in healthy volunteers after single and multiple doses. Eur J Drug Metab Pharmacokinet 1991; 16: 197-201
87. Stracciari GL, Malvisi J, Anfossi P, et al. Pharmacokinetics of dipyridamole-β-cyclodextrin complex in dogs. Arch Int Pharmacodyn 1989; 300: 7-13
88. Savolainen J, Frosberg M, Taipale H, et al. Effect of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone. Drug Dev Res 2000; 49: 238-44
89. Loftsson T, Gudmundsson JA, Árnadóttir RO, et al. Sublingual delivery of 17β-estradiol from cyclodextrin containing tablets. Pharmazie 2003; 58: 358-9
90. Fridriksdóttir H, Loftsson T, Gudmundsson JA, et al. Design and in vivo testing of 17β-estradiol-HPbCD sublingual tablets. Pharmazie 1996; 51: 39-42
91. Hoon TJ, Dawood MY, Khan-Dawood FS, et al. Bioequivalence of 17β-estradiol hydroxypropyl-β-cyclodextrin complex in postmenopausal women. J Clin Pharmacol 1993; 33: 1116-21
92. Miyaji T, Inoue Y, Acarturk F, et al. Improvement of oral bioavailability of fenbufen by cyclodextrin complexation. Acta Pharm Nord 1992; 4: 17-22
93. Géczy J, Bruhwyler J, Scuvée-Moreau J, et al. The inclusion of fluoxitine into γ-cyclodextrin increases its bioavailability: behavioral, electrophysiological and pharmacokinetic, studies. Psychopharmacology 2000; 151: 328-34
94. Zuo Z, Tam YK, Diakur J, et al. Hydroxypropyl-β-cyclodextrin-flutamide inclusion complex: II. Oral and intravenous pharmacokinetics of flutamide in the rat. J Pharm Pharm Sci 2002; 5: 292-8
95. Savolainen J, Järvinen K, Taipale H, et al. Coadministration of a water-soluble polymer increases the usefulness of cyclodextrins in solid dosage forms. Pharm Res 1998; 15: 1696-701
96. Jayachandra Babu R, Pandit JK. Enhancement of dissolution rate and hypoglycemic activity of glibenclamide with β -cyclodextrin. STP Pharma Sci 1995; 5: 196-201
97. Aggarwal S, Singh PN, Mishra B. Studies on solubility and hypoglycemic activity of gliclazide β-cyclodextrin-hydroxypropylmethylcellulose complexes. Pharmazie 2002; 57: 191-3
98. Sridevi S, Chauhan AS, Chalasani KB, et al. Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-β-cyclodextrin. Pharmazie 2003; 58: 807-10
99. Uekama K, Udo K, Irie T, et al. Improvement of dissolution and absorption characteristics of indomethacin by water-soluble α-cyclodextrin-epichlorohydrin polymer. Acta Pharm Suec 1987; 24: 27-36
100. Jambhekar S, Casella R, Maher T. The physicochemical characteristics and bioavailability of indomethacin from β -cyclodextrin, hydroxyethyl-β-cyclodextrin, and hydroxypropyl-β -cyclodextrin complexes. Int J Pharm 2004; 270: 149-66
101. Zhao Q, Zhou H, Pesco-Koplowitz L. Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. J Clin Pharmacol 2001; 41: 1319-28
102. Barone JA, Moskovitz; BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 1862-5
103. Ahn HJ, Kim KM, Choi JS, et al. Effects of cyclodextrin derivatives on bioavailability of ketoprofen. Drug Dev Ind Pharm 1997; 23: 397-401
104. Tenjarla S, Puranajoti P, Kasina R, et al. Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery. J Pharm Sci 1998; 87: 425-9
105. Otero-Espinar FJ, Anguiano-Igea S, García-Gonzales N, et al. Oral bioavailability of naproxen-β-cyclodextrin inclusion compound. Int J Pharm 1991; 75: 37-44
106. Fernandes CM, Ramos P, Falcão AC, et al. Hydrophilic and hydrophobic cyclodextrins in a new sustained release oral formulation of nicardipine: in vitro evaluation and bioavailability studies in rabbits. J Control Release 2003; 88: 127-34
107. Chowdary KPR, Kamalakara. RG. Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with β-cyclodextrin. Pharmazie 2003; 58: 721-4
108. Emara LH, Badr RM, Abd Elbary A. Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers. Drug Dev Ind Pharm 2002; 28: 795-807
109. Uekama K, Ikegami K, Wang Z, et al. Inhibitory effect of 2-hydroxypropyl-β-cyclodextrin on crystal-growth of nifedipine during storage: superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30. J Pharm Pharmacol 1992; 44: 73-8
110. Wang Z, Hirayama F, Uekama K. In-vivo and in-vitro evaluations of modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-β-cyclodextrin and hydroxypropylcellulose in dogs. J Pharm Pharmacol 1994; 46: 505-7
111. Choi H-G, Kim D-D, Jun HW, et al. Improvement of dissolution and bioavailability of nitrendipine by inclusion in hydroxypropyl-β-cyclodextrin. Drug Dev Ind Pharm 2003; 29: 1085-94
112. Savolainen J, Järvinen K, Matilainen L, et al. Improved dissolution and bioavailability of phenytoin by sulfobutylether-β-cyclodextrin (SBE)7m-β-CD) and hydroxypropyl-β-cyclodextrin (HP-b-CD) complexation. Int J Pharm 1998; 165: 69-78
113. Uekama K, Otagiri M, Irie T, et al. Improvement of dissolution and absorption characteristics of phenytoin by a water-soluble β-cyclodextrin-epichlorohydrin polymer. Int J Pharm 1985; 23: 35-42
114. Tanino T, Ogiso T, Iwaki M. Effect of sugar-modified β-cyclodextrins on dissolution and absorption characteristics of phenytoin. Biol Pharm Bull 1999; 22: 298-304
115. Woodcock BG, Acerbi D, Merz PG, et al. Supermolecular inclusion of piroxicam with β-cyclodextrin: pharmacokinetic properties in man. Eur J Rheumatol Inflamm 1993; 12: 12-28
116. McEwen J. Clinical pharmacology of piroxicam-β-cyclodextrin: implications for innovative patient care. Clin Drug Invest 2000; 19 Suppl. 2: 27-31
117. Elkheshen SA, Ahmed SM, Al-Quadeib BT. Inclusion complexes of piroxicam with β-cyclodextrin derivatives in comparison with the natural β-cyclodextrin, 2nd communication: in vitro and in vivo drug availability. Pharm Ind 2002; 64: 708-15
118. Kimura E, Bersani-Amado CA, Sudo LS, et al. Pharmacokinetic profile of piroxicam β-cyclodextrin, in rat plasma and lymph. Gen Pharmacol 1997; 28: 695-8
119. Deroubaix X, Stockis A, Allemon AM, et al. Oral bioavailability of CHF1194, an inclusion complex of piroxicam and β-cyclodextrin, in healthy-subjects under single-dose and steady-state conditions. Eur J Clin Pharmacol 1995; 47: 531-6
120. Hashimoto N, Fujioka T, Hayashi K, et al. Renin inhibitor: relationship between molecular structure and oral absorption. Pharm Res 1994; 11: 1443-7
121. Lin H-S, Chan SY, Low KSY, et al. Kinetic study of a 2-hydroxypropyl-β-cyclodextrin based formulation of all-trans-retinoic acid in Sprague-Dawley rats after oral or intravenous administration. J Pharm Sci 2000; 89: 260-7
122. Chavanpatil M, Dawre FD, Shakleya DS, et al. Enhancement of oral bioavailability of rofecoxib using β-cyclodextrin. J Incl Phenom Macroc Chem 2002; 44: 145-9
123. Miyake K, Arima H, Hirayama F, et al. Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-β-cyclodextrin. Pharm Dev Technol 2000; 5: 399-407
124. Arcari M, Brambilla A, Brandt A, et al. Nuovo complesso di inclusione tra la silibina e la b-ciclodextrina: velocità di sissoluzione in vitro e assorbimento in vivo in confronto a formulazioni tradizionali. Boll Chim Farm 1992; 131: 205-9
125. Seo H, Tsuruoka M, Hashimoto T, et al. Enhancement of oral bioavailability of spironolactone by β-and γ-cyclodextrin complexation. Chem Pharm Bull 1983; 31: 286-91
126. Kaukonen AM, Lennernäs A, Mannermaa JP. Water-soluble β-cyclodextrins in pediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of β-cyclodextrin derivatives in rats. J Pharm Pharmacol 1998; 50: 611-9
127. Soliman OAE, Kimura K, Hirayama F, et al. Amorphous spirolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability. Int J Pharm 1997; 149: 73-83
128. Arima H, Yunomae K, Miyake K, et al. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci 2001; 90: 690-701
129. Pitha J, Harman SM, Michel ME. Hydrophilic cyclodextrin derivatives enable effective oral administration of steroidal hormones. J Pharm Sci 1986; 75: 165-7
130. Stuenkel CA, Dudley RE, Yen SSC. Sublingual administration of testosterone-hydroxypropyl-β-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. J Clin Endocrinol Metab 1991; 72: 1054-9
131. Vakily M, Pasutto FM, Daneshtalab M, et al. Inclusion complexation of heptakis (2,6-di-O-ethul)-β-cyclodextrin with tiaprofenic acid: pharmacokinetic consequences of a pH-dependent release and stereoselective dissolution. J Pharm Sci 1995; 84: 1014-9
132. Veiga F, Fernandes C, Teixeira T. Oral bioavailability and hypoglycemic activity of tolbutamide/cyclodextrin inclusion complexes. Int J Pharm 2000; 202: 165-71
133. Kimura K, Hirayama F, Arima H, et al. Effects of aging on crystallization, dissolution and absorption characteristics of amorphous tolbutamide-2-hydroxypropyl-β-cyclodextrin complex. Chem Pharm Bull (Tokyo) 2000; 48: 646-50
134. Uekama K, Horiuchi Y, Kikuchi M, et al. Enhanced dissolution and oral bioavailability of α-tocopheryl esters by dimethyl-β-cyclodextrin complexation. J Incl Phenom 1988; 6: 167-74
135. Ventura P, Panini R, Montosi G, et al. Ursodeoxycholic acid complexation with 2-hydroxypropyl-β-cyclodextrin increases ursodeoxycholic acid biliary excretion after single oral administration to rats. Pharmacology 2001; 62: 107-12
136. Panini R, Vandelli MA, Forni F, et al. Improvement of ursodeoxycholic acid bioavailability by 2-hydroxypropyl-β -cyclodextrin complexation in healthy volunteers. Pharmacol Res 1995; 31: 205-9
137. Amselem S, Friedman D, Yogev A, et al. Formulation development for a zidovudine chemical delivery system: 2. Towards oral and non-parenteral dosage forms. Int J Pharm 1995; 125: 31-43
138. Goodman Gilman A, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1992
139. Ahuja N, Singh A, Singh B. Rofecoxib: an update on physicochemical, ISSN pharmaceutical, Pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol 2003; 55: 859-94
140. Kobayashi Y, Ito S, Itai S, et al. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int J Pharm 2000; 193: 137-46
141. Popovic J, Mikov M, Jakovljevic V. Pharmacokientics of carbamazepine derived from a new tablet formulation. Eur J Drug Metab Pharmacokinet 1995; 20: 297-300
142. Anderson PO, Knoben JE, Troutman WG, editors. Handbook of clinical drug data. 9th ed. Stamford: Appelton & Lange, 1999
143. Kann J, Krol G, Raemsch K, et al. Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers. J Cardiovasc Pharmacol 1984; 6 Suppl. 7: S968-73
144. Veiga M-D, Ahsan F. Hydroxypropyl gamma cyclodextrin as a solubilizer and dissolution enhancing agent: the case of tolbutamide - a poorly water-soluble drug. In: Torres Labandeira JJ, Vila-Jato JL, editors. Proceedings of the Ninth International Symposium on Cyclodextrins; 1998 Jun 3; Santiago de Compostela. Dordrecht: Kluwer Academic Publishers, 1999: 321-4
145. Peeters J, Neeskens P, Tollenaere JP, et al. Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci 2002; 91: 1414-22
146. Brewster ME, Verreck G, Chun I, et al. The use of polymer-based electrospun nanofibers containing amorphous drug dispersions for the delivery of poorly water-soluble pharmaceuticals. Pharmazie 2004 May; 59 (5): 387-91
147. Benet LZ, Øie S, Schwartz JB. Design and optimization of dosage regimens; pharmacokinetic data. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman's the pharmaceutical basis of therapeutics. New York: McGraw-Hill, 1996: 1752
148. Miyake K, Hirayama F, Uekama K. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-α- and β-cyclodextrins in aqueous solution. J Pharm Sci 1999; 88: 39-45
149. Loftsson T. Cyclodextrins and the biopharmaceutics classification system. J Incl Phenom Macroc Chem 2002; 44: 63-7
150. Lemesle-Lamache V, Wouessidjewe D, Chéron M, et al. Study of β-cyclodextrin and ethylated β-cyclodextrin salbutamol complexes, in vitro evaluation of sustained-release behavior of salbutamol. Int J Pharm 1996; 141: 117-24
151. Zannou EA, Streng WH, Stella VJ. Osmotic properties of sulfobutylether and hydroxypropyl cyclodextrins. Pharm Res 2001; 18: 1226-31
152. Stella VJ, Rao VM, Zannou EA. The pharmaceutical use of Captisol®: some surprising observations. J Incl Phenom Macroc Chem 2002; 44: 29-33
153. Koester LS, Xavier CR, Mayorga P, et al. Influence of β-cyclodextrin complexation on carbamazepine release from hydroxypropyl methylcellulose matrix tablets. Ear J Pharm Biopharm 2003; 55: 85-91
154. Rao VM, Haslam JL, Stella VJ. Controlled and complete release of a model poorly water-soluble drug, prednisolone, from hydroxypropyl methylcellulose matrix tablets using (SBE) (7M)-β-cyclodextrin as a solubilizing agent. J Pharm Sci 2001; 90: 807-16
155. Yano H, Hirayama F, Kamada M, et al. Colon-specific delivery of prednisolone-appended α-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J Control Release 2002; 79: 103-12
156. Hirayama F, Kamada M, Yano H, et al. Prolonged plasma levels of ketoprofen after oral administration of its α-cyclodextrin conjugate/ethylcellulose dispersion in rats. J Incl Phenom Macroc Chem 2002; 44: 159-61
157. Manttin E, Verhoef JC, Merkus FWHM. Efficiency, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J Drug Target 1998; 6: 17-36